Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease

Görsev Yener, Duygu Hünerli-Gündüz, Ebru Yıldırım, Tuba Aktürk, Canan Başar-Eroğlu, Laura Bonanni, Claudio Del Percio, Francesca Farina, Raffaele Ferri, Bahar Güntekin, Mihály Hajós, Agustín Ibáñez, Yang Jiang, Roberta Lizio, Susanna Lopez, Giuseppe Noce, Mario A. Parra, Fiona Randall, Fabrizio Stocchi, Claudio Babiloni

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Alzheimer's disease dementia (ADD) is the most diffuse neurodegenerative disorder belonging to mild cognitive impairment (MCI) and dementia in old persons. This disease is provoked by an abnormal accumulation of amyloid-beta and tauopathy proteins in the brain. Very recently, the first disease-modifying drug has been licensed with reserve (i.e., Aducanumab). Therefore, there is a need to identify and use biomarkers probing the neurophysiological underpinnings of human cognitive functions to test the clinical efficacy of that drug. In this regard, event-related electroencephalographic potentials (ERPs) and oscillations (EROs) are promising candidates. Here, an Expert Panel from the Electrophysiology Professional Interest Area of the Alzheimer's Association and Global Brain Consortium reviewed the field literature on the effects of the most used symptomatic drug against ADD (i.e., Acetylcholinesterase inhibitors) on ERPs and EROs in ADD patients with MCI and dementia at the group level. The most convincing results were found in ADD patients. In those patients, Acetylcholinesterase inhibitors partially normalized ERP P300 peak latency and amplitude in oddball paradigms using visual stimuli. In these same paradigms, those drugs partially normalize ERO phase-locking at the theta band (4–7 Hz) and spectral coherence between electrode pairs at the gamma (around 40 Hz) band. These results are of great interest and may motivate multicentric, double-blind, randomized, and placebo-controlled clinical trials in MCI and ADD patients for final cross-validation.

Original languageEnglish
Pages (from-to)179-201
Number of pages23
JournalInternational Journal of Psychophysiology
StatePublished - Jul 2022

Bibliographical note

Funding Information:
This manuscript was facilitated by the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART), through the Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium (GBC). The views and opinions expressed by the authors in this publication represent those of the authors and do not necessarily reflect those of the EPIA membership, ISTAART or the Alzheimer's Association, or the GBC. The EPIA is committed to exploring biomarkers for (1) improving the understanding of electrophysiological mechanisms underlying ADD and non-AD dementias, and (2) facilitating international initiatives and clinical applications. EPIA and GBC members believe that EEG biomarkers provide an important resource for research in the field of clinical and pharmacological applications in neuropsychiatric conditions, especially in low- and middle-income countries. Dr. Jiang is supported by United States National Institutes of Health (R56AG060608).

Funding Information:
Dr. Jiang is supported by United States National Institutes of Health ( R56AG060608 ).

Publisher Copyright:
© 2022 Elsevier B.V.


  • Alzheimer
  • Biomarker
  • Dementia
  • EEG
  • EROs
  • ERPs
  • Event-related
  • Mild cognitive impairment
  • Monitoring
  • Oscillations
  • P300
  • Treatment

ASJC Scopus subject areas

  • Neuroscience (all)
  • Neuropsychology and Physiological Psychology
  • Physiology (medical)


Dive into the research topics of 'Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this